<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1069">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510623</url>
  </required_header>
  <id_info>
    <org_study_id>H20-00600</org_study_id>
    <nct_id>NCT04510623</nct_id>
  </id_info>
  <brief_title>Host Response Mediators in Coronavirus (COVID-19) Infection</brief_title>
  <acronym>ARBS CORONA I</acronym>
  <official_title>Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Angiotensin II Type 1 Receptor Blockers (ARBs) on Outcomes of Coronavirus Infection?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Columbia Centre for Disease Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Victoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The coronavirus (COVID-19) pandemic continues to grow exponentially. Angiotensin II levels
      are increased in human influenza and are associated with influenza viral load, disease
      progression and mortality. Preliminary data shows angiotensin II receptor blockers (ARBs)
      limits lung injury in murine influenza H7N9, as well as viral titre and RNA. ARBs could limit
      viral titre and organ injury in COVID-19. We will therefore collect clinical chart data and
      test angiotensin II levels of patients who are admitted to ICU with COVID-19 to determine
      whether there is a correlation between taking ARBs and clinical outcomes in these patients.

      Other blood biomarkers and clinical risk factors for COVID-19 have come to light in recent
      weeks. We include these in our observational analysis to help generate an understanding of
      COVID-19 presentation and blood biomarker characterization of disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To determine whether angiotensin II receptor blockers (ARBs) decrease severity or
      mortality in hospitalized COVID-19 infected adults.

      Main Hypothesis: Modulation of ACE2 by ARBs decreases the need for hospitalization, severity
      (need for ventilation, vasopressors, extracorporeal membrane oxygenation or renal replacement
      therapy) or mortality of hospitalized COVID-19 infected adults.

      Secondary Hypotheses:

        -  Plasma angiotensin I and II and other biomarker levels are associated with effectiveness
           of ARBs in hospitalized COVID-19 adults

        -  Modulation of ACE2 by angiotensin type I receptor blockers is associated with decreased
           rate of hospitalization for COVID-19

        -  In patients already on ARBs when they are hospitalized continuing ARBs is associated
           with decreased World Health Organization (WHO) COVID-19 ordinal outcome scale

      Justification: The COVID-19 epidemic continues to grow exponentially affecting over 71,429
      individuals with 1775 deaths (February 17, 2020), mostly in China but also in other
      countries. The population mortality rate is 2% (lower than SARS (10%) and MERS (36%) but is
      10% in hospitalized and 24% in ICU-admitted COVID-19 patients in China. Recent data from
      China (not yet public domain) suggest ICU mortality is higher (J. Marshall personal
      communication). Interventions to date include quarantine, isolation and usual clinical care.
      There are no proven antiviral or host modulating interventions for COVID-19. Notably,
      critically ill COVID-19 patients have similar mortality rates as sepsis and acute respiratory
      distress syndrome. Cohort studies have shown that patients already on angiotensin-converting
      enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) have lower sepsis
      mortality. Angiotensin II worsens lung injury in influenza models because ACE2 is
      downregulated in H1N1, H5N1, H7N9, and SARS viral infections leading to increased angiotensin
      II. Angiotensin II levels are increased in human influenza and are associated with influenza
      viral load, disease progression and mortality. Preliminary data shows ARBs limits lung injury
      in murine influenza H7N9, as well as viral titre and RNA. ARBs could limit viral titre and
      organ injury in COVID-19.

      Research Design:

      Prospective clinical chart review: we will collect clinical data on the participant
      throughout their hospital stay. Includes collection of baseline characteristics such as age,
      sex, heart rate, respiratory rate, temperature, blood pressure, SaO2, respiratory
      (PaO2/FiO2), renal (creatinine) and hepatic (bilirubin) function, use of oxygen,
      vasopressors, ventilation and RRT. They will be followed daily throughout their hospital
      stay, until death or discharge. Using left over clinical blood collected upon admission to
      hospital, plasma angiotensin I and II and other biomarker levels will be measured in our
      research laboratories.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>COVID-19 WHO ordinal scale</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Organ Dysfunction</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>29 days or less (may be discharged from critical care before day 28)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital/ICU length of stay</measure>
    <time_frame>29 days or less (may be discharged before day 28)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>29 days or less (may be discharged from critical care before day 28)</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV2</condition>
  <arm_group>
    <arm_group_label>COVID-19 Patients on ARBs</arm_group_label>
    <description>This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin Receptor Blockers will be included in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 Patients on ACE inhibitors</arm_group_label>
    <description>This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin-Converting Enzyme inhibitors will be included in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 Patients on ARBs or ACE inhibitors</arm_group_label>
    <description>This is an observational cohort study. Those who have COVID-19 in hospital and are on ARBs or ACEi's will be included in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 Patients not on ARBs or ACE inhibitors</arm_group_label>
    <description>This is an observational cohort study. Those who have COVID-19 in hospital and are not on ARBs or ACEi's will be included in this cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ARBs and/or ACE inhibitors</intervention_name>
    <description>This is an observational study only.</description>
    <arm_group_label>COVID-19 Patients on ACE inhibitors</arm_group_label>
    <arm_group_label>COVID-19 Patients on ARBs</arm_group_label>
    <arm_group_label>COVID-19 Patients on ARBs or ACE inhibitors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>This is an observational study only.</description>
    <arm_group_label>COVID-19 Patients not on ARBs or ACE inhibitors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult hospitalized patients with confirmed COVID-19
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals over 18 years of age who have confirmed COVID-19 infection (according to
             local hospital or provincial laboratories clinically approved laboratory testing for
             COVID-19).

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A Russell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Paul's Hospital, Center for Heart and Lung Innovation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Puneet Mann, MSc</last_name>
    <phone>604 682 2344</phone>
    <phone_ext>64734</phone_ext>
    <email>pmann7@providencehealth.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynda Lazosky</last_name>
    <phone>604-682-2344</phone>
    <phone_ext>64886</phone_ext>
    <email>llazosky@providencehealth.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary - Foothills</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent Winston, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Joffe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksa Rewa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Surrey Memorial Hospital</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregory Haljan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Pauls Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Puneet Mann, MSc</last_name>
      <phone>604 682 2344</phone>
      <phone_ext>64734</phone_ext>
      <email>pmann7@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>James A Russell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sweet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queens University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Maslove, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humber River Hospital</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataly Farshait</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison McGeer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Marshall, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Fowler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Cheng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Lamontagne, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Jim Russell</investigator_full_name>
    <investigator_title>Study-Wide Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ARBs</keyword>
  <keyword>angiotensin II type 1 receptor blocker</keyword>
  <keyword>ACEi</keyword>
  <keyword>acute respiratory distress syndrome</keyword>
  <keyword>COVID-19</keyword>
  <keyword>coronavirus</keyword>
  <keyword>Multisite</keyword>
  <keyword>Canada</keyword>
  <keyword>Observational</keyword>
  <keyword>acute kidney injury</keyword>
  <keyword>shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

